Myeloproliferative neoplasms (MPNs) are a heterogenous group of myeloid disorders including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). All these conditions can be associated with significant morbidity including increased risk of thrombotic events as well as reduced survival. Selecting therapy is dependent on patients’ risk assessment and thus prognostication is vital in the management of these conditions. There have been significant developments in prognostic and risk stratification models for MPNs over the last few years, including incorporation of molecular markers. This narrative review article aims to summarize these prognostic models and provide practical advice on how clinicians can utilize these tools to develop personalized treatment strategies for MPN patients.
Al-Zubaidi et al. (2026) studied this question.